Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.50 |
| ▸ | STAT6 | P42226 | 5/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914085 | 0.90 | PDE4B (0.52) | PDE4BSTAT6JAK3GBA1TYRO3 | |
| SCHEMBL5914225 | 0.86 | JAK3 (0.54) | PDE4BSTAT6JAK3ZAP70SYK | |
| SCHEMBL5264926 | 0.80 | STAT6 (0.44) | PDE4BSTAT6JAK3GBA1TYRO3 | |
| SCHEMBL5316644 | 0.79 | JAK3 (0.43) | PDE4BSTAT6JAK3GBA1TYRO3 | |
| SCHEMBL5914256 | 0.77 | INSR (0.52) | GBA1 | |
| SCHEMBL5264668 | 0.75 | PDE4B (0.56) | PDE4BZAP70SYKJAK2 | |
| SCHEMBL5913955 | 0.75 | PDE4B (0.51) | PDE4BSTAT6JAK3GBA1TYRO3 | |
| SCHEMBL5264243 | 0.73 | ALDH1A1 (0.48) | JAK3TYRO3 | |
| SCHEMBL5316176 | 0.72 | PDE4B (0.44) | PDE4BJAK3GBA1TYRO3JAK2 | |
| SCHEMBL14658533 | 0.72 | STAT6 (0.87) | STAT6JAK3ZAP70SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | claimed |
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | PDE4B 2694/4885STAT6 1201/4885JAK3 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.